Epilepsy is a neurological disorder that affects millions of people worldwide. Over the years, significant advancements have been made in its management, providing new hope for patients and healthcare professionals alike.
Technological advancements have led to the development of more precise diagnostic tools. High-density EEGs and 3D-MRI imaging now allow for a more accurate localization of seizure foci. These tools have not only improved the diagnostic accuracy but also made it possible to identify surgical candidates earlier.
Newer antiepileptic drugs (AEDs) have been developed with better efficacy and fewer side effects. Drugs such as Brivaracetam and Perampanel have shown promising results in controlling seizures. Additionally, the use of CBD-based Epidiolex has been approved for certain types of epilepsy, expanding the therapeutic options.
Surgical management of epilepsy has also evolved, with minimally invasive techniques such as Laser Interstitial Thermal Therapy (LITT) and Responsive Neurostimulation (RNS) gaining popularity. These techniques have less postoperative morbidity and can be an option for patients who are not candidates for traditional resective surgery.
Neuromodulation therapies such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Transcranial Magnetic Stimulation (TMS) have emerged as effective adjunctive treatments. These therapies offer an alternative for patients who do not respond to pharmacological treatments or are not suitable for surgery.
The advancements in epilepsy management have significantly improved the quality of life for many patients. As healthcare professionals, it is imperative to stay updated with these advancements to provide the best care possible. These innovations, coupled with a personalized approach to treatment, will continue to improve the prognosis and quality of life for individuals living with epilepsy.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation